The continued promise and many disappointments of oncolytic virotherapy in gastrointestinal malignancies

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Oncolytic virotherapy represents a novel therapeutic strategy in the treatment of gastrointestinal malignancies. Oncolytic viruses, including genetically engineered and naturally occurring viruses, can selectively replicate in and induce tumor cell apoptosis without harming normal tissues, thus offering a promising tool in the armamentarium for cancer therapy. While this approach has garnered much interest over the past several decades, there has not been significant headway across various tumor types. The recent approval of talimogene laherparepvec, a second-generation oncolytic herpes simplex virus type-1, for the treatment of metastatic melanoma, confirms the therapeutic potential of oncolytic viral therapy. Herein, we will highlight and review the role of oncolytic viral therapy in gastrointestinal malignancies while discussing its limitations and potential alternative mechanisms to improve its treatment efficacy.

Original languageEnglish (US)
Article number10
JournalBiomedicines
Volume5
Issue number1
DOIs
StatePublished - Mar 1 2017

Fingerprint

Oncolytic Virotherapy
Viruses
Tumors
Neoplasms
Oncolytic Viruses
Therapeutics
Cells
Tissue
Apoptosis
Human Herpesvirus 1
Melanoma

Keywords

  • Immunotherapy
  • Oncolytic virotherapy
  • Targeted therapies

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

The continued promise and many disappointments of oncolytic virotherapy in gastrointestinal malignancies. / Ahn, Daniel; Bekaii-Saab, Tanios.

In: Biomedicines, Vol. 5, No. 1, 10, 01.03.2017.

Research output: Contribution to journalReview article

@article{4412fed56b654f96a6f4b6ecadd1fe32,
title = "The continued promise and many disappointments of oncolytic virotherapy in gastrointestinal malignancies",
abstract = "Oncolytic virotherapy represents a novel therapeutic strategy in the treatment of gastrointestinal malignancies. Oncolytic viruses, including genetically engineered and naturally occurring viruses, can selectively replicate in and induce tumor cell apoptosis without harming normal tissues, thus offering a promising tool in the armamentarium for cancer therapy. While this approach has garnered much interest over the past several decades, there has not been significant headway across various tumor types. The recent approval of talimogene laherparepvec, a second-generation oncolytic herpes simplex virus type-1, for the treatment of metastatic melanoma, confirms the therapeutic potential of oncolytic viral therapy. Herein, we will highlight and review the role of oncolytic viral therapy in gastrointestinal malignancies while discussing its limitations and potential alternative mechanisms to improve its treatment efficacy.",
keywords = "Immunotherapy, Oncolytic virotherapy, Targeted therapies",
author = "Daniel Ahn and Tanios Bekaii-Saab",
year = "2017",
month = "3",
day = "1",
doi = "10.3390/biomedicines5010010",
language = "English (US)",
volume = "5",
journal = "Biomedicines",
issn = "2227-9059",
publisher = "MDPI AG",
number = "1",

}

TY - JOUR

T1 - The continued promise and many disappointments of oncolytic virotherapy in gastrointestinal malignancies

AU - Ahn, Daniel

AU - Bekaii-Saab, Tanios

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Oncolytic virotherapy represents a novel therapeutic strategy in the treatment of gastrointestinal malignancies. Oncolytic viruses, including genetically engineered and naturally occurring viruses, can selectively replicate in and induce tumor cell apoptosis without harming normal tissues, thus offering a promising tool in the armamentarium for cancer therapy. While this approach has garnered much interest over the past several decades, there has not been significant headway across various tumor types. The recent approval of talimogene laherparepvec, a second-generation oncolytic herpes simplex virus type-1, for the treatment of metastatic melanoma, confirms the therapeutic potential of oncolytic viral therapy. Herein, we will highlight and review the role of oncolytic viral therapy in gastrointestinal malignancies while discussing its limitations and potential alternative mechanisms to improve its treatment efficacy.

AB - Oncolytic virotherapy represents a novel therapeutic strategy in the treatment of gastrointestinal malignancies. Oncolytic viruses, including genetically engineered and naturally occurring viruses, can selectively replicate in and induce tumor cell apoptosis without harming normal tissues, thus offering a promising tool in the armamentarium for cancer therapy. While this approach has garnered much interest over the past several decades, there has not been significant headway across various tumor types. The recent approval of talimogene laherparepvec, a second-generation oncolytic herpes simplex virus type-1, for the treatment of metastatic melanoma, confirms the therapeutic potential of oncolytic viral therapy. Herein, we will highlight and review the role of oncolytic viral therapy in gastrointestinal malignancies while discussing its limitations and potential alternative mechanisms to improve its treatment efficacy.

KW - Immunotherapy

KW - Oncolytic virotherapy

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=85035333826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035333826&partnerID=8YFLogxK

U2 - 10.3390/biomedicines5010010

DO - 10.3390/biomedicines5010010

M3 - Review article

AN - SCOPUS:85035333826

VL - 5

JO - Biomedicines

JF - Biomedicines

SN - 2227-9059

IS - 1

M1 - 10

ER -